Clinical Trials

9 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

16 enrolled

Cholangiocarcinoma

NCT03601455 2026-05-11

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

13 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

25 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

8 enrolled 9 charts

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

NCT07122089 2026-05-05

IOSPHERE

80 enrolled

Carcinoma, Hepatocellular

NCT03482102 2026-05-04

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

37 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04585490 2026-05-04

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Phase 3 Recruiting

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07166406 2026-05-04

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Phase 3 Recruiting

226 enrolled

Carcinoma, Hepatocellular

NCT06710223 2026-04-30

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

20 enrolled

Carcinoma, Hepatocellular

NCT06045975 2026-04-24

DUMELEP

30 enrolled

Phase 1 Active not recruiting

Carcinoma, Hepatocellular

NCT04605731 2026-04-20

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

25 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT06855225 2026-04-17

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Liver Neoplasms

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

535 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

40 enrolled

Phase 1 Active not recruiting

Carcinoma, Hepatocellular

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07489976 2026-03-27

IIT2025-03-YANG-LIFT-HCC

41 enrolled

Hepato Cellular Carcinoma

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03753919 2026-03-11

DUTHY

Phase EARLY_PHASE1 Active not recruiting

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

54 enrolled

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

90 enrolled

Pancreatic Neoplasms

NCT06608940 2026-02-19

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Liver Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

55 enrolled

Carcinoma, Hepatocellular

NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

NCT06904170 2026-02-03

ALICE

Phase 2/3 Recruiting

196 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Hepatocellular

NCT06824363 2026-01-30

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

34 enrolled

Adenocarcinoma Of Esophagus

NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

39 enrolled

Carcinoma, Hepatocellular

NCT03539822 2026-01-21

CAMILLA

Phase 1/2 Recruiting

117 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

19 enrolled 12 charts

Mesothelioma

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

32 enrolled

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT05380713 2025-12-29

......SMARTEST Trial......

Other solid neoplasmThoracic

30 enrolled

Mesothelioma, Malignant

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

50 enrolled

BreastDermatologicGastrointestinalThoracic

Cholangiocarcinoma

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

53 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Carcinoma, Hepatocellular

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

14 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT06698250 2025-11-06

ZENOBIA

40 enrolled

Carcinoma, Hepatocellular

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Other solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Phase 1/2 Recruiting

52 enrolled

Mesothelioma

NCT02938793 2025-09-23

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

92 enrolled

Neoplasms, Rare Diseases

NCT03026062 2025-09-19

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

100 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Phase 1 Completed

13 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms

NCT06999694 2025-09-10

Proton-STRIDE

45 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT02962063 2025-09-05

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

64 enrolled

Adenocarcinoma Of Esophagus

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

20 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

21 enrolled 12 charts

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT02029001 2025-08-07

MOST plus